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1. Introduction
Alzheimer disease (AD), was first recognized in the early 1900’s by Alois Alzheimer, a German
psychiatrist and neuro pathologist and named after him (Fig.1). Auguste Deter, in 1902 is a
reported patient of Dr. Alois (Fig.2). AD is the most common form of dementia affecting
millions of the geriatric population worldwide, mostly those above 65-85 yrs of age. Women
are more commonly affected than man [1]. Alzheimer currently afflicts about 5.2 million
Americans and with the rapid escalation of the prevalence of the disease, the figure is expected
to double by 2020. According to WHO, there are about 18 million people worldwide with AD,
the figure will be projected to nearly double by 2025 to 34 million. Developing countries like
India and China will be among the countries worst hit by AD due to ageing of the population
and likely some genetic factors. In 2000, India had 3.5 million Alzheimer patients, however
with the fast graying of population and growth rate being fastest in the 80+ segment of the
society, the number of Alzheimer patients have been growing at a phenomenal rate [2]. This
neurodegenerative fatal brain disorder generally begins in late life and disease progression is
gradual and continuous, the longevity of a patient is about 8-10 yrs after symptoms appear.
The disease conditions range from mild, moderate to severe; in mild conditions patients have
some functional impairments, in moderate conditions there’s a dependence on care givers for
some important daily activities, in severe conditions there is complete neuronal and memory
loss, motor impairment making the patient absolutely dependent on care givers. Age related
behavioral changes and symptoms of Alzheimer should not be confused.
Typical clinical symptoms of Alzheimer include: signs of progressive memory loss disturbing
daily activities, difficulty in completing daily activities, poor judgment, vision problems, sudden
changes in mood and personality, self withdrawal from hobbies or social contacts, loss of
cognition, loss of coordination, etc. Ageing is the greatest risk factor of AD though Alzheimer is
not a normal part of aging since people below 65yrs of age can also develop AD referred to as
‘younger or early onset’ [1,2]. The differences between a normal aged brain and the brain of an
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Alzheimer patient have been depicted in Fig.3. Other prominent risk factors in AD include family
history, heredity (genetics), environmental factors. A genetic factor in late onset AD is ApoE ε4.
The gene for apolipoprotein E (ApoE) on chromosome 19 has gained much recent attention in
the pathogenesis of AD. ApoE is a protein modulator of phospholipid transport that might have
a role in synaptic remodeling. ApoE has three common alleles, ApoE ε2, ε3, and ε4, which are
expressed in varying amounts in the normal person. It is the ApoE ε4 genotype that is associat‐
ed with the risk of AD. Everyone inherits one form of APoE gene from each parent; those who
receive ApoE ε4 gene are at the risk of developing AD than those who receive ApoE ε2, ApoE
ε3. Individuals who inherit two ApoE ε4 genes are at even higher risk; however inheriting one
or two copies of genes does not gurantee that the individual will develop Alzheimer [3,4,5].
Moderate and severe head trauma, traumatic brain injuries are associated with increased risk of
AD. Head injury resulting in loss of consciousness or post traumatic amnesia lasting about 30mins
is associated with twice the risk of developing AD; severe head injuries have about 4.5 fold risks.
Mild cognitive impairment (MCI) has an established link with AD in which a person has problems
with memory, language, and some essential cognitive ability severe enough to be noticeable to
others and shown upon cognitive tests but not severe enough to interfere with the daily life.
However there is no clear explanation on the fact that why some people with MCI develops
dementia and in some cases it is not. The overall health of the heart and blood vessels shows a
close linkage with the brain health since a brain is nourished by the rich network of blood vessels
and a healthy heart pumps nutrient and oxygen rich blood to these vessels. Cardiovascular
diseases, high blood pressure, hypertensions, type 2 diabetes, cholesterolemia, obesity, smoking
habits, and physical inactivity potentially increases the risk of AD [6-9].
2. Patho physiology of Alzheimer
The human brain consists of 100 millions of neurons connected to each other through synapses
forming communication network; each cells entitled to perform their own duties relating to
Figure 1. Dr. Alois Alzheimer(1864-1915)
Figure 2. Auguste Deter (1902), patient of Dr. Alois
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memory, thinking, smell, taste, emotions etc. In case of AD these brain cells can’t perform their
duties. Patho physiology of Alzheimer disease being complex and multi factorial shows
important pathological changes in brain like accumulation of amyloid cerebral plaques and
neurofibrillary tangles of abnormal insoluble ‘tau’ protein (Fig.6,8,9). AD is also considered a
‘tauopathy’ due to abnormal aggregation of the tau protein. Every neuron has a cytoskeleton,
an internal support structure partly made up of structures called microtubules. These micro‐
tubules act like tracks, guiding nutrients and molecules from the body of the cell to the ends
of the axon and back. A protein called tau stabilizes the microtubules when phosphorylated,
and is therefore called a microtubule-associated protein. In AD, tau undergoes chemical
Figure 3. Alzheimer disease diagram, normal aged brain (left), Alzheimer brain (right)
Figure 4. Shrinkage of Brain tissue in Alzheimer disease
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changes, becoming hyperphosphorylated; it then begins to pair with other threads, creating
neurofibrillary tangles and disintegrating the neuron's transport system [10,11].
As per the amyloid hypothesis, the neuropathologic hallmarks of AD are neuritic plaques and
neurofibrillary tangles, consisting of hyper-phosphorylated microtubule-associated protein
called ‘tau’ and extracellular amyloid plaques. The main component of amyloid plaques in AD
is amyloid β (Aβ) peptide (38–43 amino acids) which is a proteolytic by-product from the
amyloid precursor protein (APP) generated by the sequential β-secretase and γ-secretase
cleavage (Fig.7). Research data have been shown that oligomeric Aβ species (smallest of which
are dimers) isolated from AD brains are the most synaptotoxic forms. Aggregated amyloid
fibrils, which are believed to be the toxic form of the protein disrupts the cell's calcium ion
homeostasis, induces programmed cell death or apoptosis (Fig.7). It is also known that Aβ
selectively builds up in the mitochondria in the cells of Alzheimer's-affected brains, and it also
inhibits certain enzyme functions and the utilization of glucose by neurons [3,11-13].
The brain of a Alzheimer patient shows marked histo-pathophysiological changes like,
widened sulci and shrinkage of the gyri (Fig.10). In the great majority of cases, every part of
the cerebral cortex is involved; however, the occipital pole is often relatively spared. The
cortical ribbon may be thinned and ventricular dilatation apparent, especially in the temporal
horn, due to atrophy of the amygdala and hippocampus. Microscopically, there is significant
loss of neurons, in addition to shrinkage of large cortical neurons, synapses, in association with
shrinkage of the dendritic arbor of large neurons, is thought to be the critical pathological
substrate (Fig.4). Neurofibrillary tangles are the other characteristic neurohistopathologic
hallmarks seen in AD. These tangles found inside the neurons, concentrated in vulnerable
Figure 5. Normal homeostasis of Alzheimer Disease
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neural systems and composed of paired helical filaments of hyperphosphorylated micro-
tubule-associated tau protein that may cause disruption of normal cytoskeletal architecture
with subsequent neuronal cell death. Other pathological alterations commonly seen in the
brains of AD patients include neuropil threads, granulovacuolar degeneration, and amyloid
angiopathy. Amyloid angiopathy is a distinct vascular lesion found in many AD brains,
consisting of amyloid deposition in the walls of small-to medium-sized cortical and leptome‐
ningeal arteries. As a result of the deposits, the involved vessels may become compromised
with resultant hemorrhage [14-17].
Inflammatory processes and cytokines play a controversial role in the pathology of Alzheimer's
disease. Inflammation is a general marker of tissue damage in any disease, and may be either
Figure 6. Normal Neuron (left), Neurofibrillary tangles, Amyloid plaques in Alzheimer (right)
Figure 7. Enzyme action on APP (Amyloid precursor protein) and its fragmentation
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secondary to tissue damage in AD or a marker of an immunological response. Some studies
have demonstrated the presence of activated microglia, a marker of the brain’s immune
response. Alterations in the distribution of different neurotrophic factors and in the expression
of their receptors such as the brain derived neurotrophic factor (BDNF) have been found in
AD. Microglia have been shown to be significantly activated in AD brains and localized at sites
of amyloid deposition. Early activation of microglia in early AD pathogenesis has been shown
to be beneficial in scavenging and clearing toxic Aβ from the brain. Peri vascular macrophages
like CD163 (hemoglobin-haptoglobin scavenger receptor) and CD206 (mannose receptor) are
antigen-presenting phagocytic cells located in outer aspects of blood vessels within the brain,
have shown to respond to CNS inflammation. Results of clinical trials have shown that, blood-
derived macrophages from AD patients were shown to be less effective at phagocytosing Aβ
compared with cells derived from non-demented control patients. Microglial and peri vascular
macrophages may play role in clearing Aβ from the brain and in enhancing AD-related
inflammation [18-20].
Figure 8. Neuro-fibrillary tangle with hyperphosphorylated Tau Protein(high resolution)
Neurodegenerative Diseases296
Figure 9. Changes in Tau protein & disintegration of microtubules in brain cells
Figure 10. Histopathologic image of senile plaques in Alzheimer Brain
Vascular dysfunction has a critical role in AD. Results of epidemiological and pathological
studies have demonstrated positive links between cerebro vascular disorders and AD. For
example a person with severe atherosclerosis is at a threefold increased risk of developing AD
or vascular dementia. Due to reduced cerebral blood flow in AD there are abnormal cholinergic
innervations of intra cerebral blood vessels leading to brain hypo perfusion. Results of recent
investigations have shown that, the upregulation of two transcription factors myocardin
(MYOCD) and serum response factor (SRF) in AD lead to arterial hypercontractility potenti‐
ating reduced cerebral blood flow. Other vascular anatomical defects observed in AD include
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atrophy and irregularities of arterioles and capillaries, increase in collagen IV, heparin sulfate
proteoglycans and laminin deposition in the basement membrane, disruption of the basement
membrane, reduced total micro vascular density, occasional swelling of astrocytic endfeets,
and extensive degeneration of the endothelium during the disease progression [21-24].
Decreased cerebral blood flow (CBF) has a negative impact on the protein synthesis necessary
for memory and learning, and may eventually lead to neuritic injury and neuronal death.
Moreover due to cerebral hypo perfusion amyloid β-peptide (Aβ) clearance across the blood–
brain barrier (BBB) will be impaired leading to accumulation of Aβ on cerebral blood vessels
and brain parenchyma causing cerebral amyloid angiopathy (CAA), which is associated with
cognitive decline and is another significant factor in the pathogenesis of AD. CAA can severely
disrupt the integrity of the blood vessel wall resulting in micro or macro intra cerebral
bleedings that exacerbates neurodegenerative process and inflammatory response and may
lead to hemorrhagic stroke. Cerebral amyloid angiopathy (CAA) with Aβ deposits in the
vascular smooth muscle cell layer is a major pathological threat to the neurovascular unit in
AD [13,17,20,21].
Research evidences have suggested that imbalances between Aβ production and clearance
from the brain cause accumulation of Aβ in the wall of cerebral vessels and in the brains of
AD individuals. Aβ that is produced both in the brain and periphery by a number of different
cell types is transported across the BBB via receptor-mediated transcytosis; the key receptors
being involved are: RAGE (Receptor for Advanced Glycation End products) that transports
Aβ from the blood into the brain and LRP (low-density lipoprotein receptor related protein-1)
that is the major cell surface Aβ clearance receptor that transports Aβ out of the brain across
the BBB and promotes Aβ clearance on VSMC. Aβ is not only cleared from the brain interstitial
fluid (ISF) as a soluble peptide, but can also be transported by its chaperone proteins in the
ISF, such as apolipoprotein E (apoE), apolipoprotein J, and α2-macroglobulin. Apart from
direct Aβ clearance into the blood, alternative perivascular route for the clearance of Aβ in the
human brain also exists. The pulsation force of cerebral blood vessels has been proposed to
drive an Aβ drainage route along the perivascular spaces. Vessel constriction or stiffening
reduces the pulsatile blood flow which in turn reduces Aβ clearance along the perivascular
spaces leading to increase in Aβ deposition in the arterial wall of AD patients [20-24].
ApoE is a reactive apolipoprotein that exists in 3 iso forms (apoE2, apoE3, and apoE4) in
humans has a major function in the transport of lipids and cholesterol in our body. Individuals
who carry at least one apoE4 allele have great chances to develop AD. ApoE, an Aβ chaperone
protein is found to be associated with impaired transport of Aβ across the BBB. Free Aβ can
be rapidly cleared from the brain mainly via LRP or RAGE receptor mediated transcytosis, but
Aβ-ApoE complexes (mostly apoE4-Aβ complexes in contrast to apoE2-Aβ and apoE3-Aβ
complexes) are cleared by the very low-density lipoprotein receptor at a much slower rate,
causing Aβ retention in the brain. Transport of Aβ via the receptor for advanced glycation
endproducts (RAGE) across the BBB provides a major source of Aβ that can deposit in the
brain and can directly lead to neuroinflammation by activating nuclear factor-κB mediated
secretion of pro-inflammatory cytokines, such as tumor necrosis factor-α and interleukin 6 that
may reduce the BBB potency [13,17,24-29].
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Figure 11. Cascade of events in Alzheimer Disease
From the genetic point of view it has been found that the distribution of cerebrovascular amyloid
in AD varies with apoE genotype and specifically the increasing dose of apoE4 alleles has been
associated with increased CAA. Understanding the cellular and molecular mechanism by which
apoE genotype influences the pathogenicity of the disease process in AD individuals can act as
important targets in developing new therapeutic interventions and diagnostic aids for AD.
Interactions of Aβ with human Vascular Smooth Muscle Cells has been found to significantly
increase the activation of matrix metalloproteinase 2 (MMP2) via increasing the mRNA expres‐
sion of membrane type 1 (MT1)-MMP, the primary MMP2 activator at the cell surface. MMP9
specifically has been found in postmortem AD tissue in significant amounts. Activated MMP9
can degrade basement membranes, extracellular matrix proteins and tight junction proteins
subsequently damaging the integrity of the BBB and potentially leading to spontaneous cerebral
hemorrhages. Similarly high levels of ROS in AD may damage proteins essentials for impor‐
tant neurovascular mechanisms. The breakdown of the BBB may in turn disrupt the normal
transport of nutrients, vitamins and electrolytes across the BBB, which are essential for proper
neuronal functioning. Therefore, therapies that reduce ROS, MMP2, and MMP9, or that block
RAGE-Aβ interaction may offer potentially useful strategies to correct BBB dysfunction in AD
[12,25,27-30].
Research data of epidemiological studies have shown controversial results as regards the
association between APOE polymorphism and the rate of progression of cognitive decline in
AD after onset. Some reports have suggested that homozygous APOE ε4 patients have more
rapid cognitive and functional decline following clinical disease onset, but an MRI study on a
large cognitively normal population showed rate of volume decrease of entorhinal cortex and
hippocampus suggesting potential development. Thus though the role of APOE in the
predisposition of AD is well established, still further studies are needed to understand the
possible association of APOE with rate of AD progression. The cascade of events in Alzheimer
disease is depicted in Fig.11.
3. Diagnosis of Alzheimer
Alzheimer's disease is usually diagnosed clinically from the patient history, collateral history
from relatives, and clinical observations, based on the presence of characteristic neurological
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and neuropsychological features and the absence of alternative conditions. Advanced medical
imaging technologies like computed tomography (CT) or magnetic resonance imaging (MRI),
single photon emission computed tomography (SPECT) or positron emission tomography
(PET) can be used to study the cerebral histo pathophysiological conditions of Alzheimer's
disease. The Alzheimer's Disease and Related Disorders Association (now known as the
Alzheimer's Association) have set up certain criteria for AD diagnosis which points to eight
cognitive domains that are most commonly impaired in AD—memory, language, perceptual
skills, attention, constructive abilities, orientation, problem solving and functional abilities.
The presence of such symptoms should be confirmed by neuropsychological testing for a
clinical diagnosis of possible or probable AD. A histopathologic confirmation including a
microscopic examination of brain tissue is required for a definitive diagnosis. In addition to
histopathologic confirmation, definite AD requires the clinical finding of dementia as deter‐
mined by the Mini-Mental State Examination (MMSE) or other standardized neuropsycho‐
logical testing; the examination must demonstrate deficits in two or more areas of cognition,
with progressive memory loss in the absence of delirium. Assessment of intellectual function‐
ing including memory testing can further characterize the state of the disease. The diagnosis
can be confirmed with very high accuracy post-mortem when brain material is available and
can be examined histologically. Neuropsychological screening tests can help in the diagnosis
of AD. In the tests, people are instructed to copy drawings similar to the one shown in the
picture, remember words, read, and subtract serial numbers. Neuropsychological tests such
as the mini-mental state examination (MMSE), are widely used to evaluate the cognitive
impairments needed for diagnosis. More comprehensive test arrays are necessary for high
reliability of results, particularly in the earliest stages of the disease. Neurological examination
in early AD will usually provide normal results, except for obvious cognitive impairment,
which may not differ from that resulting from other diseases processes, including other causes
of dementia. Interviews of family members and informations from caregivers about the
patient’s daily living abilities, the person’s mental function are very important in this regard.
Psychological tests for depression are also employed, since depression can either be concurrent
with AD, an early sign of cognitive impairment, or even the cause [3,4,22].
With the advancements in imaging technology, computed tomography (CT) and magnetic
resonance imaging (MRI) can be used to study the cortical atrophy, disproportionate volume
loss in the medial temporal lobe structures and also normal age related changes that may be
present at the early onset of disease. Functional imaging studies like the positron emission
tomography (PET) and single-photon emission computed tomography (SPECT) scans, can be
used as a diagnostic tool, which demonstrate hypometabolism and hypoperfusion, respec‐
tively, in the temporal-parietal regions bilaterally; for neuro imaging to confirm a diagnosis of
Alzheimer's in conjunction with evaluations involving mental status examination (Fig.12). In
a person already having dementia, SPECT appears to be superior in differentiating Alzheimer's
disease from other possible causes, compared with the usual attempts employing mental
testing and medical history analysis. Amyloid burden imaging compounds are under devel‐
opment. A new technique known as PiB PET has been developed that uses carbon-11 PET
scanning for directly and clearly imaging beta-amyloid deposits in vivo using a tracer that
binds selectively to the A-beta deposits with high levels of accuracy in predicting which people
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with mild cognitive impairment will develop Alzheimer's disease within two years. Volumet‐
ric MRI can detect changes in the size of brain regions and measure the atropy in those regions
in order to study the progress of AD. Amyloid imaging used in conjunction with other markers
can serve as an important diagnostic tool [3,4].
Figure 12. PET scan in the brain of Alzheimer patient (loss of function in temporal lobe)
Results of routine laboratory tests on chemistry panels, blood counts, metabolic panels (e.g., TSH)
spinal fluid analyses, and inflammatory markers are all found to be within normal limits in patients
with AD. Electroencephalographic (EEG) recordings are usually normal or show diffuse slowing
in later stages of the disease. However it has been found that in AD patients it have been found
that the levels of glutamate, creatinine, myo-inositol,  N-acetyl aspartate are decreased as
compared to normal people. Both decrease in N-acetyl aspartate/Creatinine ratio and decrease
in hippocampal glutamate may be an early indicator of AD. Monitoring the level of blood
dehydroepiandrosterone (DHEA) variations in response to an oxidative stress could be a useful
proxy test for AD since experimental research data have shown that the subjects with Mild
Cognitive Impairment did not have a DHEA variation, while the healthy controls did [3,4,8].
Another important marker of the disease is the analysis of cerebrospinal fluid for amyloid beta
or tau proteins, both total tau protein and phosphorylated tau181P protein concentrations which
predicts the onset of AD with a sensitivity of 94-100%. When used in conjunction with existing
neuro imaging techniques, doctors can identify people with significant memory loss who are
already developing the disease. Spinal fluid tests are commercially available, unlike the latest
neuro imaging technology.
The differential diagnosis for AD is extensive and includes a multitude of neurodegenerative
diseases that are associated with the development of dementia including Pick's disease, Lewy
body disease, and other diseases such as vascular dementia and Creutzfeldt-Jakob disease.
Most of these entities can be differentiated from AD by the clinical history and a careful
examination. However, the challenge lies to test new hypotheses and not just to continue
descriptive studies using better tools, technologies, increased parameters in CSF analysis and
routine lab testing’s, and more descriptions about the amount of amyloid in the brain [3,4].
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4. Therapeutic interventions in Alzheimer
Virtually there are no proven modalities for cure of Alzheimer’s disease; however there are
treatment regimens that may improve symptoms and may even delay their progression in the
early and middle stages of the disease, allowing patients to maintain certain daily functions
for longer. Various country- or region-specific, evidence-based guidelines have been devel‐
oped for the treatment of Alzheimer’s disease. These make recommendations that vary
according to available resources, funding practices, and local practice. In general, however,
the guidelines provide recommendations regarding psychiatric management, psychosocial
treatments, and the treatment of specific target symptoms. There are relatively few diseases
that have been successfully prevented or even controlled without an understanding of specific
etiology of the disease. Apart from the first line and second line FDA recommended synthetic
drugs of choice in treating AD, some of the preventive strategies proved to be beneficial in AD
include treatment of hypertension, omega fatty acid supplementation, physical activity and
cognitive engagement.
5. Conventional therapeutic regimen in Alzheimer
From the point of conventional approach, major six classes of drugs are included in the
treatment of AD: Acetylcholinesterase inhibitors (AChE-I), N-methyl-D-aspartate (NMDA)
receptor antagonists, monoamine oxidase (MAO) inhibitors, antioxidants, metal chelators,
anti-inflammatory drugs. AChE inhibitors are the first line agents for the treatment of mild to
moderate AD. FDA approved five prescription drugs to control the symptoms of AD include:
Donepezil, Galantamine, Rivastigmine, Tacrine among the AChE inhibitors and Memantine
coming under NMDA receptor antagonists. However tacrine have been withdrawn due to the
hepato toxicity effects. AChE inhibitors are prescribed to treat symptoms relating to memory,
thinking, language, judgment and other thought processes. Cholinesterase inhibitors primar‐
ily act by increasing the levels of acetylcholine, the chemical messenger involved in memory,
judgment and other thought processes. In AD the cells producing or using ACh are destroyed
and thus less amount of ACh is available to carry messages. ACh is produced from acetyl-CoA
and choline by cholineacetyltransferase which is released into the synaptic cleft and hydro‐
lyzed by the actions of AChE to choline and acetic acid. This choline is reutilized in ACh
synthesis. In the early stages of AD, the activity of AChE is found to be increased in the neuritic
plaques and neurofibrillary tangles that accelerate aggregations of beta-amyloid. AChE
inhibitors reversibly bind and block the activity of the enzyme acetyl cholinesterase that
degrades ACh. AChE inhibitors block the actions of AChE thereby facilitating ACh neuro‐
transmission and reducing beta-amyloid burden [31-34].
Basing on the cholinergic theory, different classes of drugs have been developed to enhance
cholinergic deficit in AD patients. Amongst them, AChE inhibitors block the activity of AChE
enzyme to improve cognitive function, choline precursors like phosphatidylcholine improves
the bioavailability of choline, ACh releasers enhance the release of ACh, M1 and M3 receptor
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agonists mimic ACh on postsynaptic end terminal receptors, M2 and M3 receptor antagonists
regulate ACh release via negative feedback, nicotinic agonists which would enhance ACh
release.
AChE inhibitors are mostly well tolerated by the patients; however common side effects
include nausea, vomiting, loss of appetite, increased frequency of bowel movements etc.
Tacrine, the first FDA approved AD-drug, which inhibits AChE reversibly in a non-competi‐
tive manner is no longer in use due to severe side effects (hepatotoxicity) and short biological
half life. Donepezil hydrochloride is the second drug of choice approved by USFDA for
treatment of mild to moderate AD. This drug is a centrally acting, reversible and non-
competitive AChE inhibitor having an N-benzylpiperidine and an indanone moiety which
shows longer and more selective action. However it also suffers from the side effects of GI
disturbances, nausea, vomiting, headache etc [31,33].
N
H3Co O
H3Co - HCl
Figure 13. Donepezil hydrochloride
Galantamine reversibly inhibits AChE in a competitive manner and also acts on nicotinic
acetylcholine receptors, beneficial for cognitive and non-cognitive AD symptoms. Results of
clinical trials have reported this drug to be 50 times more potent against human AChE than
butyrylcholinesterase at therapeutic doses. With escalations in drug doses some of the notable
adverse effects include vomiting, nausea, diarrhoea etc. Rivastigmine is a reversible carbamate
AChE inhibitor that interacts preferentially with acetylcholinesterase G1 with high brain
selectivity; this drug has been approved in at least 40 countries around the world. Rivastigmine
has the ability to inhibit the activity of butyrylcholinesterase. It binds to both the esteratic and
ionic locations of AChE but dissociates at a much slower rate than AChE. Metrifonate, a
precursor to the active pseudo irreversible AChE inhibitor DDVP (2,2-dichlorovinyl dimethyl
phosphate) rapidly enters the brain with a longer plasma half life than donepezil but shows
side effects of diarrhea and muscular cramps and hence could not achieve the market due to
muscular weakness. There are certain AChE inhibitors of natural origin finding its use in AD.
Physostigmine, a parasympathomimetic plant alkaloid isolated from the seeds of Physostigma
venenosum have the ability to cross the BBB, having role in cholinergic transmission, can
stimulate indirectly both nicotinic and muscarinic receptors. However physostigmine also
inhibits another enzyme butyrylcholinesterase which has a role in AD and some of the adverse
effects of this drug like nausea, vomiting, headache, diarrhea are attributed to its inhibitory
actions on butyrylcholinesterase. Despite of the advantage to cross the BBB, the short half life,
narrow margin of therapeutic index has restricted its potentiality. Galanthamine is an alkaloid
isolated from Galanthus nivalis with competitive reversible AChE inhibitory activity. Galanth‐
amine shows dual mechanism of action, AChE inhibition and allosteric modulation of nicotinic
acetyl choline receptors. This drug has 10 fold selectivity for AChE than butyrylcholinesterase.
Alpha-7 nicotinic acetylcholine receptors have a role in beta-amyloid mediated neurotoxiciy
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and since galanthamine can modulate nicotinic acetylcholine receptors it is suggested to
prevent beta-amyloid mediated neurotoxicity. Huperzine A, an alkaloid drug isolated from
club moss (Huperzia serrata) is claimed to show neuroprotective properties with significant
improvements in cognitive function and results of clinical trials have shown this drug to be
free from unexpected toxicities. This drug has attracted the attention of the scientists due to
its strong AChE activities; (-)-huperzine A, a natural isomer have shown strongest dose
dependent inhibitory activity against AChE, in comparison to commercially available syn‐
thetic drugs like donepezil, tacrine etc [31-33].
Memantine is an uncompetitive low-to-moderate affinity N-methyl-D-aspartate (NMDA)
receptor antagonist that regulates glutamate activity. Glutamate plays an essential role in
learning and memory by triggering NMDA receptors to let a controlled amount of calcium
into the nerve cell. This calcium creates the chemical environment required for information
storage. Excess glutamate on the other hand, over stimulates NMDA receptors so that they
allow too much calcium into nerve cells leading to disruption and death of these cells.
Memantine protects cells against excess glutamate by partially blocking NMDA receptors. It’s
a recently FDA approved NMDA antagonist for the treatment of cognition in moderate to
severe Alzheimer’s disease, having a half life period between 3-7 h and free from harsh adverse
side effects. Memantine can be administered with AChE inhibitors. However FDA did not
approve Memantine for mild AD. Results of clinical trials have shown small but statistically
significant improvements in mental functions and ability to perform daily activities in AD
patients [34,35].
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Figure 14. AChE inhibitors (a) Tacrine (b) Donepezil (c) Galantamine (d) Rivastigmine (e) Metrifonate (f) Huperzine
Several metal species like iron, zinc, copper, aluminum are reported to induce beta amyloid
aggregation and neurotoxicity in the brain of AD patients; results of structural evidences
showing interrelations between aluminum and Abeta, presence of iron and zinc in abnormal
high concentrations in AD patients have triggered the idea of using metal chelators as
therapeutic targets in the treatment of AD. Desferrioxamine (DFO) and Clioquinol are
clinically proven metal chelators used to treat AD patients. DFO chelates with metal ions or
aluminium and reduces its neocortical concentrations thereby delaying the progression of
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dementia associated with AD and shows behavioral improvements. However the proper
mechanism of action is not yet revealed. Transition metals like copper and zinc are found to
be in high concentrations in the neo-cortical regions of the AD patients and these metals are
mostly aggregated in the neurotic plaques potentiating beta amyloid aggregation and neuro‐
toxicity. Clioquinol chelates with these metals and reduces the beta amyloid aggregation in
the brain, thus finding use as a therapeutic target in treating Alzheimer [35].
From the pathology of Alzheimer it is clear that several neurotransmitter systems, especially
those regulating dopamine, serotonin, acetylcholine has a role in it. With the dysfunction of
the dopaminergic system, there is increase in activity of type B monoamine oxidase, the
enzyme responsible for degradation of dopamine. The increase in monoamine oxidase level
is prominent in the brain platelets contributing to the severity of dementia. The drug Selegiline
reversibly inhibits MAO-B; moreover it has a potent anti oxidative effect over the neurons of
the brain and also protect against glutamate-receptor-mediated toxicity. Apart from MAO
inhibition selegiline has a potent action in the recovery of damaged neurons involving a
number of mechanisms like stimulation of neurite outgrowth, stimulation of gene expression
in pre apoptotic neurons or stimulation of cytokine biosynthesis. Rasagiline, structurally
similar to selegiline also shows neuro protective activities and is found to be ten times more
H2N
Figure 15. Memantine
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Figure 16. Rivastigmine
O
N
R
OH
H3CO
Figure 17. Galanthamine
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active in inhibition of MAO-B. The propargylamine moiety in rasagiline is responsible for
neuro protective activities. The drug Ladostigil, is the result of combination of active com‐
pounds from rasagiline (MAO-B inhibitor, neuroprotector) and rivastigmine (AChE inhibitor)
thus finding application as a effective therapeutic agent in treating AD [33-35].
N
(a)
N
H
(b)
Figure 19. Monoamine oxidase inhibitors (a) Selegiline (b) Rasagiline
Oxidative damage to neurons has a significant role in the pathogenesis of AD; hence antioxi‐
dant therapy to prevent oxidative injury can be effective in preventing or retarding the progress
of AD. Extracts from Ginko biloba named as Egb761 have been found to show cognitive
improvement in AD patients and in those with multi-infarct dementia. Similarly Melatonin is
found to have antiamyloidogenic activities and is found to reduce neuronal damage caused
by reactive oxygen species in AD patients. Antioxidant therapy with vitamin E though
reported in some cases but it does not improve cognitive impairment and its therapeutic use
has not been established. Clinical trials with Idebenone, a co-enzyme Q10 analog have been
found to attenuate Abeta-induced neurotoxicity and cognitive impairments. Dehydroevodi‐
amine hydrochloride (DHED), a compound extracted from Evodia rutaecarpa showed AChE
inhibitory activities, DHED protects neurons against hydrogen peroxide and glutamate.
Moreover DHED decreases reactive oxygen species production and cell death induced by
Abeta and carboxyterminal peptides of amyloid precursor proteins, thus improving cognitive
impairments in AD. Metalloporphyrin antioxidants have been found to delay neuronal death
resulting from increased mitochondrial oxidative stress; Mn-salen complexes have been found
to be efficacious against oxidative stress [35].
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Cu
Figure 18. (a) Desferrioxamine (b) Ferrioxamine B (c) Clioquinol (d) Clioquinol Zn complex (e) Clioquinol Cu complex
Neurodegenerative Diseases306
OOH(a)
N
N
H
O
H
O
(b)
N
N
O
Mn NN
Br Br
Br
Br
BrBr
Br
Br
O
O
O
HO
HO
OH
OH
(c)
OHO
O O
O
O
(d)
N
N
N+
O
H Cl-
(e)
N
Mn
O
N
O
X
R R
(f)
Figure 20. Antioxidants: (a)alpha tocopherol (b) Melatonin (c) Manganese (ш) beta-octabromo-meso tetrakis (4-car‐
boxy phenyl) porphyrin (d) Idebenone (e) Dehydroevodiamine (f) Mn-salen
In AD, neuronal destruction is due to inflammation around Abeta plaques. Drugs under the
NSAID groups have anti-inflammatory actions, and found to inhibit cyclooxygenase-1 and
cyclooxygenase-2 which are responsible for the oxidation of arachidonic acids to prostaglan‐
dins; however due to adverse effects of some NSAIDs on cardiovascular systems, these group
of drugs have not found routine use in AD treatment.
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Figure 21. NSAIDs (a) Ibuprofen (b) Aspirin (c) Naproxen (d) Flubiprofen
6. Omega fatty acids in treating Alzheimer
Polyunsaturated fatty acids or PUFA have significant biological roles in cellular structure and
function. PUFA are the key components of phospholipids, comprising cellular and intracel‐
lular membranes. They govern the growth and vitality through oxidation (metabolism of food
to produce energy required for cellular processes), chemical activities and transportation. In
addition to being the structural materials for bio-membranes, PUFA are required for generat‐
ing and propagating electrical impulses; synthesis of eicosanoids, important signaling
hormones with numerous complex functions. Amongst its wide range of actions include anti-
inflammatory, anti-thrombotic and vasodilatory properties, balancing and counteracting pro-
inflammatory, vasoconstrictor actions of eicosanoids; the cardiovascular benefits of n-3 PUFA
are largely attributed to these eicosanoid properties, and at the same time having significant
roles in brain function. Polyunsaturated fatty acids like alpha linoleic acids (ALA), linolenic
acids (LA), eicosapentaenoic acids (EPA) or docosahexaenoic acids (DHA) are not synthesized
in the body and hence must be supplied in the diet [36].
Lipids constitute approximately sixty percent of the dry weight of the brain. DHA and
Arachidonic acids (AA) are the most highly concentrated PUFAs present in neural phospho‐
lipids, including sub cellular membranes. DHA is particularly concentrated at neural synapses,
retina, brain and nervous system. Though there is a predominance of omega-6 fatty acids in
circulation, in contrast to omega-3 fatty acids, however DHA predominates in these vital
structures. The amount of DHA levels in the neural phospholipids depend on the amount of
dietary intake rich in omega-3 fatty acids. Clinical studies have shown that insufficient
omega-3 PUFA during early neural development shows decreased DHA content in the brain.
The n-3 PUFAs have significant biological mechanisms in brain function. Neurotransmitters
such as dopamine and serotonin have a role in mental illness, research data have focused on
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associations between PUFA and central nervous system activity. Levels of n-3 PUFA have been
associated with monoaminergic neurotransmitter levels. There are indications that PUFA are
involved in the synthesis and activities of brain peptides, which are involved in modulating
the activities of neurotransmitters. Evidence points to the role of eicosanoids in healthy brain
functioning, and phospholipid membranes in neural cell signaling. Results of animal studies
have shown that, n-3 deficiency is found to reduce phosphatidylserine (PS) levels in the brain,
which is thought to play an important function in neural signaling activities. In alcoholics,
DHA deficiency has predicted reduced 5-hydroxyindoleacetic acid (5-HIAA) concentrations
in cerebrospinal fluid, an indicator of low serotonin turnover rate in the frontal cortex. Studies
have further indicated that n-3 PUFA may affect receptor properties or activation of signal
transduction by receptors. Electrical impulse conduction is dependent on the exchange of ions
through the cell membrane, which relies on the fluidity and physiological structure of cell
membranes. Furthermore, n-3 PUFA are also thought to influence gene expression of a range
of enzymes required for important neural functions including synaptic transduction, ion
channel formation, energy metabolism and formulation of proteins vital for brain development
and function. Regular delivery of oxygen and nutrients via the blood is also vital for optimal
brain function, and psychopathology is associated with both reduced cerebral blood flow and
transportation of glucose, the brain’s primary energy source, to brain regions as required. In
this regard, n-3 PUFA are associated with production of nitric oxide, as well as anti-inflam‐
matory and vasodilatory eicosanoids (notably PGI2), and are known to assist in endothelial-
dependent vasodilatation. They have also been associated with substantially increased
transport of glucose across the blood-brain barrier. Therefore, it is also possible that their
primary influence on brain function includes improved cerebral blood flow and blood-brain
barrier integrity. This idea is supported by the fact that there’s a high co-morbidity between
cardiovascular disease and psychopathology, having a common underlying vascular pathol‐
ogy which can be mediated by lifestyle factors such as suboptimal levels of n-3 PUFA [36].
The mechanisms by which ω-3 fatty acids could interfere in AD patho physiologic features are
not clear, but since anti-inflammatory effects are an important property of these fish oils rich
in PUFA, they are applicable for AD also. Epidemiologic evidences have shown that admin‐
istration of ω-3 fatty acid in patients with mild to moderate AD did not delay the rate of
cognitive decline according to the MMSE or the cognitive portion of the Alzheimer Disease
Assessment Scale but, positive effects were observed in a small group of patients with very
mild AD. Increased intake of the ω-3 polyunsaturated fatty acids (primarily eicosapentaenoic
acid (EPA), 20:5ω-3, and docosahexaenoic acid (DHA), 22:6ω-3) may be beneficial in reducing
risk for AD. Increased fish consumption and diets supplemented with omega-3 fatty acids are
found to exhibit a protective effect, cognitive improvement and enhancement of learning
abilities. Animal studies on transgenic mouse model of AD with DHA-enriched diets signifi‐
cantly reduced total β-amyloid by 70% when compared with diets low in DHA or control chow
diets [ext-link ext-link-type="bibr" rid="REF-NOC60062-9 REF-NOC60062-10"/].
However these findings cannot serve as a basis for general recommendations for treatment of
AD with dietary DHA-rich fish oil preparations. Rather, larger cohort’s studies in patients with
mild cognitive impairment, including those at risk for AD are needed to further explore the
potentiality of the ω-3 fatty acids in halting initial progression of the disease [36].
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7. In silico drug design in Alzheimer
Though a number of FDA approved drugs are currently available for the treatment of
Alzheimer but there are no such effective treatments to stop the insidious nerve cell death
process once the disease begins. Available drugs can manage and ease some of the symptoms
of the disease but the progression of the disease can in no way be slowed down by these
treatments. In AD patients there is very less production of neurotransmitter acetylcholine due
to the progressive damage of the cells producing acetylcholine. Most of the FDA approved
drugs aim to prevent the breakdown of acetylcholine by inhibiting the enzyme acetyl choli‐
nesterase. But in AD due to rapid destruction of nerve cells, the acetylcholine produced even
though protected from further breakdown but the amount produced is significantly insuffi‐
cient to transmit messages between the brain cells. This fact necessitates further new drug
development.
In contrast to traditional drug discovery, “Rational Drug Design’’ has been found to be a more
deterministic approach where the first necessary step is the identification of the molecular
target critical to the disease process and then determine the molecular structure of the target
molecule. In-silico drug design approach makes use of Computer Assisted Drug Design
(CADD) tools to find a ligand (putative drug) that will interact with a receptor which represents
the ‘target site’. A ligand can bind to the receptor either by hydrophobic, electrostatic or
hydrogen bonding interactions and solvation energies of the ligand and receptor sites are the
important facts to be considered in this case.
The basics behind the pathology of AD is the presence of neuritic plaques containing amyloid-
β-peptide (Aβ) and intra neuronal accumulation of tubule associated ‘tau’ protein. In order to
target therapeutic strategies basing on molecular mechanisms for AD, new drug entities can
be developed that will act directly on the Aβ or the amyloid precursor protein (APP) processing
which may include vaccination with Aβ peptide, Aβ passive immunization. However clinical
trials with a vaccine made of synthetic Aβ 1-42 showed the lateral development of encephalitis
and hence the trial was put on hold though the concept exists. Passive immunization can be
obtained by monoclonal antibodies against Aβ. New anti-amyloid agents to prevent fibrilli‐
zations can be designed by detailed characterizations of the proto fibrils and fibril formations.
Another lucrative approach is to target the APP processing where the three major enzymes
are to be targeted: alpha secretase, beta secretase and gamma secretase, the basic aim is to
increase the alpha cleavage or to decrease the beta and gamma secretase activities. Nerve
growth factors and neurotrophines can also act as important therapeutic targets. Growth factor
gene therapy (though under clinical trial) where patient’s fibroblasts transfected with NFG
and transplanted to brain are expected to be effective in case of severe AD [37].
In in -silico drug design approach, computational docking techniques can be used to develop
an effective drug to prevent the progression of Alzheimer disease. Here the ‘TARGET’ is the
amyloid precursor protein (APP) and the ‘LEAD COMPOUND’ is the protease enzyme. By
the aid of database search tools like FASTA, BLAST in Swissport, proteins having protease
activity for b-APP can be identified. Next step is to identify the protease enzyme that cleaves
the b-APP so as to prevent the formation of beta-amyloid peptide. Structural informations on
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b-APP is available from PDB (Protein Data Bank) with ID 1RW6. Soft wares like PASS, CASTp
provides information about the active site for b-APP. Enzyme modeling can be done using
packages like Swiss Model, Modeller etc. Specific interactions of these lead compounds with
the active site of b-APP can be studied by docking programs like DOCK, AUTODOCK etc. The
most effective protease enzyme with minimum energy conformation can be identified by the
above procedure which will act as the potential drug in treating Alzheimer. Use of computa‐
tional docking techniques help to explore a large number of compounds, study the binding
characteristics of ‘hits’ and is found to be effective in reducing the time and monetary expen‐
diture as associated with traditional drug development techniques [38].
8. Non-pharmacological approach
Virtually at this point of time there is no cure for Alzheimer. But apart from therapeutic
interventions, attempts can be done to manage the disease and treat the symptoms by the care
givers in a non-pharmacologic manner. Along with medications, physical exercise, social
involvement as well as proper nutrition are essential in treating the symptoms of AD. The goal
of non-pharmacologic treatment in AD though sounds simple but clinically remains a
challenge where the care giver has a vital role to play; first thing is to provide a calm structured
environment where the comfort, dignity of the afflicted person is maintained and the patient
remains functioning as long as possible [39-41]. For AD patients the environment should be
so arranged that maximize use of cognitive capacities of AD patients that are intact and
compensate for those cognitive capacities that decline. Treatment in a non-pharmacologic
manner aims to improve the quality of life to treat the disease symptoms. It is not a simple task
for a care giver to increase functional independence, reduce the need for psychoactive
medications, prolong life, reduce the need for restraints, reduce acute hospital admissions,
reduce depression and improve morale. Alzheimer begins in the medial temporal lobe and
spreads to other parts of the brain slowly destroying parietal, temporal and frontal lobes,
cingulated cortex, hippocampus, amygdale, damaging the tempero-parieto-occipital associa‐
tion cortex leading to memory dysfunction, emotional disturbances, personality changes,
visual, language and movement disorders. Due to damages in the frontal lobes AD patients
will have difficulty in performing daily tasks; with the gradual progression of the disease
hallucinations, delusions, paranoia, agitation, panic and denial are seen among the afflicted.
Among the non-pharmacologic treatment domains include: properly mapped physical
environment that removes fear and promotes safety, induce a sense of positive attitude or
emotion among the afflicted persons by the care giver while helping in daily activities by
helping them to perform the task but not to do the total task for them and make them even
more dependent; change negative emotions and promote feelings of purpose and accomplish‐
ment. While treating AD patients in non-pharmacologic manner one of the major corner stone
is how we understand the afflicted person and help him to understand himself [42-44]. The
care giver must change his/her behavior & environment in order to change the behavior of the
patient. A person in middle stage of AD should never be attempted to bring back to the realistic
world but reduce his fear in all possible stages and help him to move into his sense of the
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world. Due to sensory impairment and lack of receptive and expressive language abilities non-
verbal perceptual inputs which replace words like familiar music, known food smell, and
known touch may be used and afflicted can be communicated with a look, tone or a hug to
induce a feeling of care and safety. In case of negative behavior and aggression the triggering
agent should be identified and eliminated. The ultimate outcome of such a treatment approach
is to slow the rate of disease progression, delay institutionalization, improve the quality of life
and reduce the need for medication [39]. Below in fig.22 a specially designed room is shown
for sensory integration therapy.
Figure 22. Specially designed room for sensory integration therapy (Snoezelen); an emotion oriented psychosocial in‐
tervention for people with dementia
9. Conclusions
There is an increasing emergency in finding a prevention or treatment for AD and dementia
because of the aging of the populations and realizing the severity and complications associated
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with this deadly disease. Fortunately, AD and dementia research is now at a progressing stage.
Availability of improved medical imaging technologies like CT scan, MRI, PET, use of
biomarkers helps in early diagnosis of the disease, its progression and severity. Furthermore,
pharmacological and non-pharmacological therapies could be directly tested both to prevent
and delay the progression of amyloid in the brain and effects on brain morphology and
cognitive decline. Pharmacological therapies that could delay the onset of dementia for several
years could result in a substantial reduction in the prevalence of AD because the patients will
die of another cause before they develop AD. A second and far more important approach will
be the application of these new technologies to understand the etiology of AD. The identifi‐
cation of specific etiological factors is much more likely in the long term to have a major impact
on the incidence, prevalence, and disability because of AD and dementia. Proper understand‐
ing the etiology of the disease is essential to develop hypothetical treatment approaches which
can be further clinically established. Basing on in-silico drug design approaches it is essential
to understand the molecular mechanisms of APP processing, role of folate and homocysteine
in neuronal homeostasis. Main target should be to develop novel therapeutic agents via cost
effective, eco-friendly methodologies. Along with specific drug therapy, lifestyle interventions
and environmental variables are also to be targeted to reduce the incidence of AD. However
in case of new drug research in Alzheimer, ability to utilize the technologies, clinical skills and
financial resources to support research studies are of vital importance.
Author details
Analava Mitra* and Baishakhi Dey
*Address all correspondence to: analavamitra@gmail.com
School of Medical Science and Technology, IIT Kharagpur, India
References
[1] Basics of Alzheimer diseaseAlzheimer association (2011).
[2] Alzheimer Disease facts and FiguresAlzheimer’s & Dementia. Alzheimer association
(2011). , 7(2), 1-68.
[3] Yamasaki, T, Muranaka, H, Kaseda, Y, Mimori, Y, & Tobimatsu, S. Understanding
the pathophysiology of Alzheimer disease and mild cognitive impairment: A mini
review on fMRI and ERP studies. Neurology Research International (2011). , 20(12),
1-10.
[4] Gary, S. W. Barry RPV, Buckholtz PP, Dekosky NS, Ferris ST et al. Diagnosis and
treatment of Alzheimer disease and related disorders: consensus statement of the
American Association for Geriatric Psychiatry, the Alzheimer Association and the
Therapeutic Interventions in Alzheimer Disease
http://dx.doi.org/10.5772/54915
313
American Geriatrics Society. Journal of the American Medical Association (1997). ,
278(16), 1-9.
[5] Verghese, P. B, Castellano, J. M, & Holtzmann, D. M. Roles of Apolipoprotein E in
Alzheimer’s disease and Other Neurological Disorders. Lancet Neurology (2011). ,
10(3), 241-252.
[6] Kuller, L. H, & Lopez, O. L. Dementia and Alzheimer’s disease: A new direction. The
2010 Jay L. Foster Memorial Lecture. Alzheimer’s Dement (2011). Doi:j.jalz.
2011.05.901, 7(5), 540-550.
[7] Guidelines for Alzheimer Disease ManagementCalifornia Workgroup on Guidelines
for Alzheimer’s disease Management (2008).
[8] Winslow, B. T, Onysko, M. K, Stob, C. M, & Hazlewood, K. A. Treatment of Alzheim‐
er Disease. American Family Physician website www.aafp.org/afp.
[9] Alzheimer’s disease and Dementia-A Growing ChallengeNational Academy on an
Aging Society (2000).
[10] Bell, R. D, & Zloklovic, B. V. Neurovascular mechanisms and blood brain barrier dis‐
order in Alzheimer’s disease. Acta Neuropathologica (2009). Doi:s00401-009-0522-3,
118(1), 103-113.
[11] Alonzo, N. C, Hyman, B. T, Rebeck, G. W, & Greenberg, S. M. Progression of cerebral
amyloid angiopathy: accumulation of amyloid-beta40 in affected vessels. Journal of
Neuropathology and Experimental Neurology (1998). Doi:, 57, 353-359.
[12] Asahina, M, Yoshiyama, Y, & Hattori, T. Expression of matrix metalloproteinase-9
and urinary-type plasminogen activator in Alzheimer’s disease brain. Clinical Neu‐
ropathology (2001). , 20, 60-63.
[13] Attems, J, Jellinger, K. A, & Lintner, F. Alzheimer’s disease pathology influences se‐
verity and topographical distribution of cerebral amyloid angiopathy. Acta Neuropa‐
thologica (2005). Doi:s00401-005-1064-y., 110, 222-231.
[14] Attems, J, Quass, M, Jellinger, K. A, & Lintner, F. Topographical distribution of cere‐
bral amyloid angiopathy and its effect on cognitive decline are influenced by Alz‐
heimer disease pathology. Journal of Neurological Sciences (2007). Doi:10.1016/j.jns.
2007.01.013., 257, 49-55.
[15] Bailey, T. L, Rivara, C. B, Rocher, A. B, & Hof, P. R. The nature and effects of cortical
microvascular pathology in aging and Alzheimer’s disease. Neurological Research
(2004). Doi:, 26, 573-578.
[16] Begley, D. J, & Brightman, M. W. Structural and functional aspects of the blood-brain
barrier. Progress in Drug Research (2003). , 61, 39-78.
[17] Bell, R. D, Sagare, A. P, Friedman, A. E, et al. Transport pathways for clearance of
human Alzheimer’s amyloid beta-peptide and apolipoproteins E and J in the mouse
Neurodegenerative Diseases314
central nervous system. Journal of Cerebral Blood Flow and Metabolism (2007). , 27,
909-918.
[18] Corder, E. H, Saunders, A. M, Strittmatter, W. J, et al. Gene dose of apolipoprotein E
type 4 allele and the risk of Alzheimer’s disease in late onset families. Science. (1993).
Doi:10.1126/science.8346443., 261, 921-923.
[19] Deane, R, Bell, R. D, Sagare, A, & Zlokovic, B. Z. Clearance of amyloid-beta peptide
across the blood-brain barrier: implications for therapies in Alzheimer’s disease. CNS
and Neurological Disorders- Drug Targets (2009). Doi:
[20] Deane, R. Du Yan S, Submamaryan RK, et al. RAGE mediates amyloid-beta peptide
transport across the blood-brain barrier and accumulation in brain. Nature Medicine
(2003). Doi:nm890., 9, 907-913.
[21] Deane, R, Wu, Z, Sagare, A, et al. LRP/amyloid beta-peptide interaction mediates dif‐
ferential brain efflux of Abeta isoforms. Neuron. (2004). Doi:10.1016/j.neuron.
2004.07.017., 43, 333-344.
[22] Drzezga, A, Lautenschlager, N, Siebner, H, et al. Cerebral metabolic changes accom‐
panying conversion of mild cognitive impairment into Alzheimer’s disease: a PET
follow-up study. European Journal of Nuclear Medicine and Molecular Imaging
(2003). Doi:s00259-003-1194-1., 30, 1104-1113.
[23] Ervin, J. F, Pannell, C, Szymanski, M, Welsh-bohmer, K, Schmechel, D. E, & Hulette,
C. M. Vascular smooth muscle actin is reduced in Alzheimer disease brain: a quanti‐
tative analysis. Journal of Neuropathology and Experimental Neurology (2004). , 63,
735-741.
[24] Grabowski, T. J, Cho, H. S, Vonsattel, J. P, Rebeck, G. W, & Greenberg, S. M. Novel
amyloid precursor protein mutation in an Iowa family with dementia and severe cer‐
ebral amyloid angiopathy. Annals of Neurology (2001). Doi:10.1002/ana.1009., 49,
697-705.
[25] Jung, S. S, Zhang, W, & Van Nostrand, W. E. Pathogenic A beta induces the expres‐
sion and activation of matrix metalloproteinase-2 in human cerebrovascular smooth
muscle cells. Journal of Neurochemistry (2003). Doi:10.1046/j.1471-4159.2003.01745.x.,
85, 1208-1215.
[26] Parks, J. K, Smith, T. S, Trimmer, P. A, & Bennett, J. P. Jr, Parker WD., Jr Neurotoxic
Abeta peptides increase oxidative stress in vivo through NMDA-receptor and nitric-
oxide-synthase mechanisms, and inhibit complex IV activity and induce a mitochon‐
drial permeability transition in vitro. Journal of Neurochemistry (2001). Doi:10.1046/j.
1471-4159.2001.00112.x., 76, 1050-1056.
[27] Preston, S. D, Steart, P. V, Wilkinson, A, Nicoll, J. A, & Weller, R. O. Capillary and
arterial cerebral amyloid angiopathy in Alzheimer’s disease: defining the perivascu‐
Therapeutic Interventions in Alzheimer Disease
http://dx.doi.org/10.5772/54915
315
lar route for the elimination of amyloid beta from the human brain. Neuropathology
and Applied Neurobiology (2003). Doi:10.1046/j.1365-2990.2003.00424.x., 29, 106-117.
[28] Rosenberg, G. A. Matrix metalloproteinases and their multiple roles in neurodege‐
nerative diseases. Lancet Neurology (2009). Doi:S1474-4422(09)70016-X., 8, 205-216.
[29] Sagare, A, Deane, R, Bell, R. D, et al. Clearance of amyloid-beta by circulating lipo‐
protein receptors. Nature Medicine (2007). Doi:nm1635., 13, 1029-1031.
[30] Ushijima, Y, Okuyama, C, Mori, S, Kubota, T, Nakai, T, & Nishimura, T. Regional
cerebral blood flow in Alzheimer’s disease: Comparison between short term and
long term donepezil therapy. Annals of Nuclear Medicine (2006). , 20(6), 425-429.
[31] Sugimoto, H, Yamanishi, Y, Limura, Y, & Kawakami, Y. Donepezil hydrochloride
(E2020) and other Acetylcholinesterase Inhibitors. Current Medicinal Chemistry
(2000). , 7-303.
[32] Orhan, G, Orhan, I, Oztekin, N. S, Fikri, A. K, & Sener, B. Contemporary Anticholi‐
nesterase Pharmaceuticals of Natural Origin and their Synthetic Analogues for the
Treatment of Alzheimer Disease. Recent Patents on CNS Drug Discovery (2009). , 4,
43-51.
[33] Woodruff Pak DS, Vogel RW, Wenk GL. Mecamylamine Interactions with Galanta‐
mine and Donepezil: Effects on Learning, Acetylcholinesterase and Nicotinic Acetyl‐
choline Receptors. Neuroscience (2003). , 117-439.
[34] Sugimoto, H. Structure-activity relationships of acetylcholinesterase inhibitors: Do‐
nepezil hydrochloride for the treatment of Alzheimer’s disease. Journal of Pure and
Applied Chemistry (1999). , 71(11), 2031-2037.
[35] Suh, W. H, Suslick, K. S, & Suh, Y. H. Therapeutic agents for Alzheimer Disease. Cur‐
rent Medicinal Chemistry-Central Nervous System Agents (2005). , 5-259.
[36] Sinn, N, & Milte, C. Howe PRC. Oiling the Brain: A Review of Randomized Control‐
led Trials of Omega-3 Fatty Acids in Psychopathology across the Lifespan. Nutrients
(2010). , 2(2), 128-170.
[37] Religa, D, & Winblad, B. Therapeutic strategies for Alzheimer Disease based on new
molecular mechanisms. Acta Neurobiol Express (2003). , 63-393.
[38] Kandavelmani, A. Alzheimer Disease: In silico Drug Design-An Endeavour. Bioinfor‐
matics India (2005). , 3(2), 25-28.
[39] Zeisel, J, & Raia, P. Non-pharmacological Treatment for Alzheimer Disease: A mind-
brain approach. American Journal of Alzheimer Disease and Other Dementias
(2000). , 15(6), 331-340.
[40] Weiner, M. F, & Gray, K. F. Balancing Psychosocial and Psychopharmacologic meas‐
ures in Alzheimer Disease. The American Journal of Alzheimer’s Care and Related
Disorders and Research (1994). , 9(4), 6-12.
Neurodegenerative Diseases316
[41] Martichuski, D. K, & Bell, P. A. Treating excess disabilities in special care units: A Re‐
view of interventions. The American Journal of Alzheimer’s Care and related disor‐
ders and Research (1993). , 5-8.
[42] Reisberg, B, Kenowsky, S, & Franssen, E. Souren LEM, Shulman E, Steinberg G, Ar‐
onstein Z, Auer S. Slowing the progression of Alzheimer Disease: Towards a Science
of Alzheimer Disease care. Caring (1996). , 2(2), 2-4.
[43] Morton, I, & Bleathman, C. The effectiveness of validation therapy in dementia: a pi‐
lot study. International Journal of Geriatric Psychiatry (1991). , 6-327.
[44] Sclan, S, Saillon, A, Franssen, E, et al. The Behavioral Pathology in Alzheimer’s dis‐
ease Rating Scales (BEHAVE-AD): Reliability and Analysis of symptom category
scores. International journal of Geriatric Psychiatry (1996). , 11-819.
Therapeutic Interventions in Alzheimer Disease
http://dx.doi.org/10.5772/54915
317

